SCHEMBL2350889

SCHEMBL2350889

O=C(O)CCc1cc(F)c(OCc2cccc3ccccc23)c(F)c1

nearest known ligand 0.67

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 5/20 0.67
AKR1B1 P15121 1/20 0.67
THRA P10827 5/20 0.52
THRB P10828 5/20 0.52
FFAR4 Q5NUL3 10/20 0.51
TDP1 Q9NUW8 1/20 0.46
ESR1 P03372 1/20 0.45
NR3C1 P04150 1/20 0.45
PGR P06401 1/20 0.45
NR3C2 P08235 1/20 0.45
AR P10275 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
PARP10 Q53GL7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898411 0.86 THRA (0.70) FFAR1AKR1B1THRATHRBFFAR4
SCHEMBL2353946 0.86 FFAR1 (0.51) FFAR1AKR1B1THRATHRBFFAR4
SCHEMBL6064208 0.82 THRA (0.75) FFAR1THRATHRBFFAR4
SCHEMBL2347446 0.81 FFAR4 (0.67) FFAR1THRATHRBFFAR4
SCHEMBL1746720 0.81 FFAR1 (1.00) FFAR1AKR1B1FFAR4PARP10
SCHEMBL2349128 0.80 THRA (0.55) FFAR1THRATHRBFFAR4PARP10
SCHEMBL6062633 0.80 THRA (0.59) FFAR1THRATHRBFFAR4
SCHEMBL6063512 0.80 FFAR1 (0.56) FFAR1AKR1B1THRATHRBFFAR4
SCHEMBL2353079 0.80 THRA (0.54) FFAR1AKR1B1THRATHRBFFAR4
SCHEMBL2351164 0.79 FFAR1 (0.70) FFAR1THRATHRBFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1688138-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2006-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167378-A1 Receptor Function Regulation Agent GPR119, INSR, GPR88 FFAR1 16/4885AKR1B1 825/4885THRA 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.